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Over a 30 month period from 1987 to 1990, selective hepatic cannulation under fluoroscopic control was
performed in 57 consecutive patients with primary and secondary malignancies of the liver. Fifty-three
patients were subsequently treated using intra-arterial Lipiodol emulsified with epirubicin. The tumours
treated were hepatocellular carcinoma (n 35), metastatic adenocarcinoma (n 14), intrahepatic
cholangiocarcinoma (n 3) and leiomyosarcoma (n 1). For hepatocellular carcinoma the cumulative
survival was 38% at one year; the median survival was 12.2 months for Stage I, 6.3 months for Stage II
and 0.9 months for Stage III tumours.
In metastatic disease the cumulative survival was 63% at one year.
These data suggest that targeted intra-arterial chemotherapy with Lipiodol-epirubicin is a useful
palliative therapy for patients with Stage and II HCC, and that a controlled trial of this treatment
should be undertaken.
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INTRODUCTION
Primary liver cancer or hepatocellular carcinoma (HCC) is one of the commonest
and most malignant tumours in the world. It is especially prevalent in South-east
Asia and Japan, where it ranks second only to stomach cancer, and in Sub-saharan
Africa1, where the incidence may be as high as 100 cases per 100,000 males per
year2. Whilst the incidence is increasing in the United Kingdom3, it remains far
below that of secondary liver tumours which complicate one third of all extrahepa-
tic malignant disease. This is particularly true for colorectal cancer, where 20% of
patients have multiple liver metastases at the time of their initial surgery. Up to
50% of all patients who present with colorectal carcinoma will eventually develop
liver deposits, but in many cases the liver is the only site of recurrent disease
following a successful resection of the primary tumour4. The treatment of choice in
both primary hepatocellular carcinoma and metastatic disease is surgical resection,
but this is possible in less than a quarter of patients1’4’5.
The prognosis is bleak in those patients with irresectable hepatic disease.
Systemic chemotherapy and radiotherapy have a relatively low therapeutic index,
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resulting in toxic side effects which are often unacceptable to the patient. This is
partly a result of the high doses which are necessary to produce effective levels in
tumour tissue.
Lipiodol Ultra-Fluid (May & Baker, England) is a lipid compound containing
475 mg of iodine per ml derived from poppyseed oil: it has been used for many
years as a lymphographic contrast medium. When injected into the hepatic artery it
is selectively retained in foci of hepatic tumour.In 1983 Konno et al. reported a
reduction in tumour size and in concentrations of circulating tumour marker in 13
out of 14 patients with HCC following hepatic arterial infusion of Lipiodol mixed
with the oily anticancer agent SMANCS (Styrene-maleic-anhydride-
neocarzinostatin)6. A subsequent study of 124 oriental patients with primary and
secondary liver tumours demonstrated significantly greater survival following
infusion of a Lipiodol and SMANCS combination than hepatic artery ligation and
chemotherapy7. Good response rates and increased survival have been reported
using Lipiodol in combination with other cytotoxic agents including doxorubicin,
mitomycin and cisplatinumTM. The purpose of this study was to extend these initial
findings by evaluating the efficacy and safety of Lipiodol-epirubicin therapy in a
pilot group of patients with hepatic neoplasms.
PATIENTS, MATERIALS AND METHODS
All patients with unresectable malignant tumours confined to the liver who were
referred to this unit between November 1987 and February 1990 were offered
Lipiodol-epirubicin treatment. Fifty-seven patients were entered into the study and
fifty-three were treated. The treated tumours comprised thirty-five hepatocellular
carcinomas, three intrahepatic cholangiocarcinomas, fourteen metastatic adenocar-
cinomas and one metastatic sarcoma. All had tumours which were initially
considered unresectable, although hepatic resection was subsequently attempted in
four patients. Surgery was contraindicated in multiple tumours involving both lobes
of the liver, in the elderly, in patients with advanced cirrhosis in the surrounding
liver parenchyma and in those with severely disordered hepatic function.
Four patients were excluded from treatment. In two anomalies of the hepatic
artery prevented cannulation, and two patients were found to have total occlusion
of the portal vein. No patients were excluded from Lipiodol-targeted therapy on
the grounds of age, tumour size, impaired liver function or other possible adverse
prognostic factors. The treated patients comprised 47 caucasians, 3 of oriental
origin and 3 negroes. There were 39 men and 14 women, with a mean age of 58
years (range 34-81 years).
A histological diagnosis was obtained in 33 of 35 patients with hepatocellular
carcinoma. In the two patients with a negative biopsy a hypervascular appearance
at angiography in combination with a raised serum alpha fetoprotein (AFP) was
regarded as diagnostic of HCC. In thirty-four patients the hepatocellular tumour
occurred in a cirrhotic liver; one patient had a recurrence of a fibrolamellar tumour
following previous resection. All hepatocellular tumours were staged according to
the classification of Okuda
12 (Figure 1). Five patients had Stage 1 tumours at
diagnosis (including two with newly-diagnosed recurrence following hepatic resec-
tion), 23 had Stage II malignancy, and 7 patients had Stage III tumours.LIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 225
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Figure 1 Staging of HCC (Okuda, 1985).
Of the 14 metastatic adenocarcinomas of gut origin, 10 were diagnosed at the
time of resection of the primary tumour. Three patients developed metachronous
hepatic lesions which were found on routine follow up, of whom two underwent
partial hepatectomy with subsequent recurrence. The remaining patient presented
with massive hepatomegaly: biopsy revealed a poorly differentiated adenocarci-
noma but no primary tumour was identified. The known primary tumours com-
prised 12 carcinomas of colorectal origin and one gastric carcinoma. In the patient
with metastatic leiomyosarcoma the diagnosis was made on liver biopsy.
All three patients with intrahepatic cholangiocarcinoma underwent percutaneous
stent insertion for relief of obstructive jaundice prior to Lipiodol administration.
Five patients (4 with colorectal metastases and one with cholangiocarcinoma)
received systemic chemotherapy with 5FU and Mitomycin C in addition to
Lipiodol-targeted treatment.
Intra-arterial Lipiodol-epirubicin injections were repeated at 2-3 monthly inter-
vals in patients who showed no clinical deterioration. Serum levels of AFP and
CEA were measured at diagnosis and before each treatment. Each patient received
40-120 mg of epirubicin (Pharmorubicin; Farmitalia, Italy), a water soluble
cytotoxic agent which has been shown to possess equivalent activity against HCC
and lower toxicity than its parent drug doxorubicin13. The dose for each patient was
calculated on the basis of body surface area, liver function, and nutritional state
(Table 1).
Table 1 Formulation of Lipiodol-epirubicin emulsion.
Epirubicin75 mg/m2.
Reduced by 25% if Bilirubin > 30 umol/l.
Reduced by 50% if Bilirubin > 100 umol/l.
Lipiodoll0 ml.
Urografin (Sodium meglumine diatrizoate) 10 ml.
Since epirubicin is not lipid-soluble, the drug was dissolved in 10ml of 60%
sodium meglumine diatrizoate (Urografin 290). This solution was then mixed for 5
mins with 10ml of Lipiodol using a Pulsatron ultrasonic agitator (Kerry Ultrasonics
Ltd, England). The resulting stable colloidal emulsion was selectively infused into
the hepatic artery via a catheter inserted into the femoral artery.
ACT scan of the liver was performed 10 days after each treatment when the
Lipiodol had cleared from the non-neoplastic liver parenchyma. Deposits of HCC
were typically hypervascular and showed a dense, even distribution of the lipid226 J. R. NOVELL ET AL.
(Figure 2), whereas uptake by metastases was less reliable and more commonly at
the periphery of the tumour (Figure 3). The three patients with cholangiocarci-
noma had characteristically hypovascular tumours and showed poor uptake of the
Lipiodol emulsion.
Figure 2 Ct scan of liver showing dense uptake of Lipiodol in hepatocellular carcinoma.
RESULTS
Survival
Hepatocellular carcinoma
Four patients who underwent surgery within 2 months of their first treatment were
excluded from analysis. Three of these had attempted resection of the tumour, all
of whom succumbed to postoperative complications associated with their cirrhosis.
One patient underwent liver transplantation and has subsequently died of recurrent
disease.
Thirty one patients with HCC are evaluable: all have been followed for a
minumum of 6 months from the start of treatment. Nineteen patients have died
from progression of their tumour, and two from unrelated conditions. The
cumulative survival at one year was 38% with a median survival of 6.0 months fromLIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 227
Figure 3 CT scan of liver showing peripheral uptake of Lipiodol in metastatic adenocarcinoma.
diagnosis for all patients (range 0.5-27.0 months). The median survival by stages
was as follows: Stage 1 tumours 12.2 months (range 6.5-14.8 months); Stage II
tumours 6.3 months (range 1.3-27.0 months); Stage III tumours 0.9 months (range
0.5-1.5 months). The patient with recurrent fibrolamellar disease is alive and well 6
months following treatment. The cumulative survival of patients in each stage is
summarised in Figure 4.
Secondary tumours
One patient underwent a successful resection of his tumour following the first
treatment, and was excluded from analysis. Thirteen patients with metastatic
adenocarcinoma are evaluable. Five patients are surviving between 6 and 13
months from the start of treatment, and eight died from tumour progression. The
cumulative survival at 1 year was 63% (Figure 5), and the median survival was 11.0
months from diagnosis (range 0.5-27 months). Excluding those cases treated with
systemic chemotherapy the median survival was 10 months (range 0.5-13 months).
The patient with metastatic leiomyosarcoma is alive and well five months following
Lipiodol-epirubicin treatment.
Cholangiocarcinoma
The three patients with intrahepatic cholangiocarcinoma died from tumour pro-
gression at 4.2, 12.3 and 20.9 months from diagnosis.228 J. R. NOVELL ETAL.
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Figure 4 Survival in HCC by stage.
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Inhibition of Tumour Growth
Changes in tumour size were assessed on CT scans obtained 10 days following each
treatment. Enlargement of hepatic tumour loci was evident in all three patients
with cholangiocarcinoma and in 21 of the 37 patients (57%) with Stage I/II HCC
and metastatic disease. Survival in Stage III HCC was too brief to allow reassess-
ment of tumour size. In the remainder of patients with Stage I/II hepatocellular and
metastatic tumours no increase in tumour volume was apparent on serial scans for
periods of between 4 and 21 months (Figure 6). No consistent reduction in tumour
size on serial CT scans was seen in any of the patients.
Tumour Markers
Prior to Lipiodol therapy the serum alpha fetoprotein level (AFP) was elevated in
22 patients with HCC (63%). Of these patients, only two showed a fall in AFP
following treatment, and in one patient this was not sustained on subsequent
treatments. One patient in whom the AFP was initially normal subsequently
developed a raised serum level in association with progression of his disease after
11 months of treatment.
The serum CEA level was elevated in 9 patients with metastatic disease at
diagnosis. Following the first treatment a fall occurred in two patients, one ofwhom
maintained a normal level over 3 successive treatments; a further rise in CEA was
associated with the development of lymphatic metastases.
Technical Complications
Four patients did not receive Lipiodol-targeted treatment due to vascular problems
encountered at cannulation. In two, anomalies of the coeliac vascular tree pre-
vented hepatic artery cannulation. The procedure was abandoned in two other
patients who were found to have a total occlusion of the portal vein, because of the
potentially lethal consequences of arterial occlusion. In one patient dissection of
the hepatic artery occurred during cannulation: a successful treatment was adminis-
tered 2 weeks later. Two patients developed an occlusion of the hepatic axtery,
each following 4 treatment episodes: further treatments were successfully adminis-
tered via collaterals from the superior mesenteric artery. No haematoma, femoral
artery thrombosis or false aneurysm occurred in any patient.
Adverse Effects
These were graded according to World Health Organisation criteria4. The most
frequent side effects were pyrexia (37-39C, Grade 1-2) which occurred in 83
treatments (74%), and elevation of serum transaminase levels in 75 treatments
(67%). Abnormalities in liver function tests persisted for up to 10 days following
therapy.
Three of seven patients with Stage III HCC died from treatment-related
complications. Two patients with poor hepatic function developed fulminant liver
failure following targeted chemotherapy, leading to death within 48 hours in both
cases. The third patient developed Grade 4 leucopaenia and pneumonia and
despite supportive therapy died 3 weeks later. There were no treatment-related
deaths in patients with Stage I/II HCC, cholangiocarcinoma, or metastatic disease.230 J. R. NOVELL ET AL.
Figure 6 A, B, C, D: Serial CT scans showing stasis in large hepatocellular carcinoma over a period of
18 months during treatment with Lipiodol-epirubicin.LIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 231
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Other side effects were mild and transient. Mild to moderate abdominal pain
occurred in patients (9%), and nausea and vomiting (Grade 1-2) in a further 8
cases (15%). Four patients (7%) developed partial, reversible alopecia (Grade 1-
2) following treatment. No diarrhoea, mucositis or cardiac toxicity occurred in any
patient.
DISCUSSION
The prognosis in liver cancer remains poor, and these tumours are a major cause of
mortality worldwide. Less than 25% of cases are potentially curable by surgery. For
the majority of patients, therefore, improved palliation represents the only hope of
prolonged survival.
Although up to one third of patients show a partial response to systemic
chemotherapy, the benefit is often short-lived and there is no good evidence that it
increases survival even if given by regional perfusion15. The possibility of specifi-
cally targeting therapy to tumours has thus been greeted with enthusiasm, particu-
larly in Japan where Lipiodol "chemoembolisation" is now the first line treatment
for inoperable hepatocellular carcinoma. Lipiodol-targeted chemotherapy has also
been employed in tumours of the lung, gallbladder and pancreas
16 and of the
bladder17.
The precise mechanisms of Lipiodol retention remain speculative. In particular,
there is much debate as to whether this is an embolic phenomenon, with the
Lipiodol being trapped in the microvasculature of the tumour circulation, or uptake
by a population of tumour cells. In vivo microscopy of the liver following Lipiodol
injection has shown active uptake of the lipid by cells of the reticulo-endothelial
systemTM. The lipid is cleared from normal liver within a few days, possibly by
shunting into the hepatic veins via the sinusoids.
The technique of "chemoembolisation" requires a limited number of feeding
vessels which constitute the sole or principal arterial supply to a tumour, and in this
respect the liver is particularly well suited anatomically. Another advantage of
targeted chemotherapy in liver tumours is the very low incidence of associated
toxicity. This is partly due to the efficiency of the liver macrophages in "scaveng-
ing" oily emulsionsTM, and partly a function of the high first-pass metabolism of
cytotoxics such as epirubicinI9. These factors result in lower plasma levels of the
drug and few systemic side effects, as this study confirms. In contrast, over 50% of
patients receiving systemic chemotherapy with epirubicin exhibit symptoms of
immediate and early toxicity including leucopaenia, alopaecia and vomiting2.
Despite previous reports to the contrary8’9, it is not our experience that
Lipiodol-targeted chemotherapy results in either tumour shrinkage or reduction in
levels of circulating markers. In terms of conventional response criteria, therefore,
no response was seen in any patient. However, in about half of the cases studied a
plateau in tumour growth was observed, in association with continued clinical
wellbeing, for periods of between 4 and 21 months. No data is available on the
stability of the Lipiodol-epirubicin emulsion within tissues, but it seems reasonable
to postulate that the Lipiodol-epirubicin emulsion acts as a slow release prep-
aration, inhibiting local tumour growth. Alternatively, tumour necrosis resulting
from the treatment may not be evident on hepatic imaging. In theory the use of a
more effective cytotoxic "warhead" such as the isotope Iodine-131 would result inLIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 233
greater tumour destruction. Such a vehicle is now available and early experience
from clinical trials has been encouraging, with reduction in tumour size and ascites
and symptomatic improvement in the majority of patients21’22. We are currently
investigating 131I-Lipiodol as a treatment for both HCC and cholangiocarcinoma.
This was an uncontrolled study, and it is therefore unwise to be too dogmatic
about the efficacy of Lipiodol-targeted chemotherapy. However, the overall
survival of patients with Stage I and II HCC in this study is better than previously
published rates for patients receiving systemic chemotherapy
13 and for untreated
patients12, in whom the prognosis is uniformly poor. Results in Stage III tumours
remains dismal with a median survival of less than one month.
In conclusion, our experience with Lipiodol-targeted chemotherapy in nearly 60
patients suggests that in patients with Stage I and II hepatocellular carcinoma it
is a safe technique with a low complication rate. Systemic side effects are less
frequent and less severe than those reported with intravenous chemotherapy. No
significant reductions in tumour volumes were observed during treatment, but
survival in these patients was promising. Randomised controlled trials of
Lipiodol-targeted therapy are indicated in patients with Stage I and II tumours.
The technique appears of no value in the palliation of Stage III HCC and carries a
significant mortality in this group. Likewise, in the small number of patients with
cholangiocarcinoma or metastatic tumours in this series, no convincing benefit was
seen.
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INVITED COMMENTARY
Both transcatheter arterial embolization and intraarterial infusion chemotherapy
have been utilized to treat patients with regional tumors at M.D. Anderson Cancer
Center. In primary and metastatic hepatic neoplasms both arterial tumors emboli-
zation and infusion chemotherapy showed an improved tumor response rate when
compared with traditional systemic chemotherapy. In a group of patients with
hepatic metastases from colon carcinoma who failed systemic chemotherapy,
intraarterial infusion chemotherapy with the same drugs yielded a 43% response
rate.
The combination of arterial embolization, infusion chemotherapy, and che-
moembolization has also been attempted to achieve maximal tumor response.
Chemoembolization theoretically, results in ischemia, increased capillary permea-
bility and an increased contact time between the cytotoxic agent and the tumor
cells. This has been performed in several fashions: (1) embolization of one lobe and
infusion of the non-embolized lobe, (2) sequential embolization and infusion of the
same lobe, (3) chemoembolization using chemotherapeutic drugs mixed with
arterial occlusive particulates, (4) microcapsule embolization and (5) chemoembo-
lization using oily substance as a carrier for chemotherapeutic drugs.
Chemoembolization using Cisplatin mixed with Gelfoam powder or segments
(Upjohn Inc., Kalamazoo, MI) or Ivalon particles (Polyvinyl alcohol foam,LIPIODOL CHEMOTHERAPY OF LIVER TUMOURS 235
Unipoint Laboratories, High Point, NC) has resulted in an improved tumor
response in patients with metastatic ocular melanoma to liver and pelvic tumors in
our institution2. Chemoembolization using microcapsules or starch particles has
also been attempted to combine the effect of embolization and chemotherapy in
various tumors3’4.
The use of an oily substance such as Lipiodol Ultrafluid (Ethiodol), the
ethylester of poppyseed oil containing Iodine, as a drug carrier represents another
form of chemoembolization. It has been shown in operative specimens that
Lipiodol does retain the lipid soluble Adriamycin, however this may not be valid
for water soluble cytotoxic agents. Hypervascular neoplasms are more responsive.
Preliminary reports from several centers of chemoembolization using
Lipiodol-drug mixture have demonstrated improved tumor response with a reduc-
tion of tumor size and vascularity5-8. In the current study by Novell et al., using
Lipiodol-epirubicin mixture for chemoembolization, arrest of tumor progression
was observed in half of the patients, but none had a significant reduction in tumor
size. The discrepancy of the tumor response rate between this and other Japanese
series suggests that epirubicin as the sole agent for Lipiodol chemoembolization
was less effective than other agents such as Adriamycin, Mitomycin, Cisplatin,
SMANCS, or other drugs in combinations. The addition of other chemotherapeutic
drugs into the Lipiodol-epirubicin combination would appear to be warranted in
their future study.
In oioo microscopy of the rat liver after Lipiodol injection into the hepatic artery
by Kan et al., showed that large amounts of Lipiodol entered the portal vein
through arterioportal shunting, then reached the hepatic sinusoids and eventually
exited from the hepatic veins9. In over thirty patients who received chemoemboli-
zation using a mixture of Ethiodol, multiple drugs and arterial blocking agents
(Ivalon particles; and Angiostat, Regional Therapeutics Inc., Santa Monica, CA),
we have observed portal vein opacification by Ethiodol in two patients, thus
confirming the presence of arterioportal shunting in the human liver.
Although the microcirculation of human liver might not be exactly similar to that
of the rat liver, the presence of arterioportal shunting is alike. Chemoembolization
of human liver using oily substance results in combined arterial and portal
embolization, or total hepatic parenchymal and tumoral embolization. However,
due to fast clearance of Lipiodol from the normal sinusoids within several hours to
days and prolonged existence of Lipiodol within the tumor for weeks to months,
most patients have tolerated Lipiodol chemoembolization without significantly
higher complications than those who received other embolization methods.
Because of the total hepatic embolization nature of Lipiodol chemoembolization
intentional segmental infarction of the liver had been achieved by this method1. It
is imperative that for palliative control of hepatic neoplasm not be excessive and
only segmental or lobar hepatic embolization, instead of total hepatic emboliza-
tion, is performed at one setting.
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